CAS 163252-36-6|Clevudine

Introduction：Basic information about CAS 163252-36-6|Clevudine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Clevudine BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Synonyms

Common Name	Clevudine
CAS Number	163252-36-6	Molecular Weight	260.21900
Density	1.55g/cm3	Boiling Point	/
Molecular Formula	C₁₀H₁₃FN₂O₅	Melting Point	184-185°
MSDS	/	Flash Point	/

Names

Name	1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
Synonym	More Synonyms

Clevudine BiologicalActivity

Description	Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].
Related Catalog	Signaling Pathways >>Anti-infection >>HBVResearch Areas >>Infection
References	[1]. Lee, H.S., et al., A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2006. 43(5): p. 982-8. [2]. Jang, J.H., et al., Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat, 2011. 18(2): p. 84-90.

Description

Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].

Related Catalog

Signaling Pathways >>Anti-infection >>HBVResearch Areas >>Infection

References

[1]. Lee, H.S., et al., A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2006. 43(5): p. 982-8.

[2]. Jang, J.H., et al., Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat, 2011. 18(2): p. 84-90.

Chemical & Physical Properties

Density	1.55g/cm3
Melting Point	184-185°
Molecular Formula	C₁₀H₁₃FN₂O₅
Molecular Weight	260.21900
Exact Mass	260.08100
PSA	104.55000
Index of Refraction	1.592
InChIKey	GBBJCSTXCAQSSJ-XQXXSGGOSA-N
SMILES	Cc1cn(C2OC(CO)C(O)C2F)c(=O)[nH]c1=O
Storage condition	-20°C

Safety Information

Hazard Codes	Xi
HS Code	2934999090

Customs

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synonyms

CLEVUDINE

Clevudine

Levovir

L-FMAU

Recommended......